<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00950170</url>
  </required_header>
  <id_info>
    <org_study_id>3082B2-4434</org_study_id>
    <secondary_id>B1831006</secondary_id>
    <secondary_id>2008-008436-93</secondary_id>
    <nct_id>NCT00950170</nct_id>
  </id_info>
  <brief_title>Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting</brief_title>
  <official_title>An Open-label Study Of The Safety And Efficacy Of Refacto Af In Previously Untreated Patients In Usual Care Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the safety and effectiveness of ReFacto AF for the treatment of severe
      hemophilia A in patients who have not yet received treatment for their hemophilia. Study
      subjects will be males less than 6 years old who have not taken any clotting factor or other
      blood products before the study. The safety and effectiveness of ReFacto AF will be
      determined in this study by tests and procedures done at the doctor's office.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Regulatory Commitment
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who develop clinically significant FVIII inhibitors during the course of the study.</measure>
    <time_frame>12 years (study duration)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized bleeding rates.</measure>
    <time_frame>12 years (study duration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responses to the first on-demand treatment with Refacto AF for all new bleeds.</measure>
    <time_frame>12 years (study duration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of ReFacto AF infusions to treat each new bleed.</measure>
    <time_frame>12 years (study duration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of bleeds within 48 hours of a prophylaxis dose of ReFacto AF.</measure>
    <time_frame>12 years (study duration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The average infusion dose and total factor consumption</measure>
    <time_frame>12 years (study duration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects who require dose escalation of their prescribed prophylaxis regimen during their participation in this study.</measure>
    <time_frame>12 years (study duration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of less-than-expected therapeutic effect (LETE).</measure>
    <time_frame>12 years (study duration)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigator treats subjects with ReFacto AF in the usual care setting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laboratory Tests</intervention_name>
    <description>Blood draws to determine the level of factor VIII activity before and after dosing at appropriate visits, and blood draws to determine levels of factor VIII inhibitor (antibody to factor VIII).</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ReFacto AF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects &lt;6 years of age with severe hemophilia A (FVIII:C &lt;1%) based on clinical
             records, including newborns.

          -  No prior exposure to factor products or any blood products.

        Exclusion Criteria:

          -  Presence of any bleeding disorder in addition to hemophilia A.

          -  Treatment with any investigational agent or device within the past 30 days.

          -  Any condition(s) that compromises the ability to collect study-related observations,
             or that poses a contraindication to study participation (these conditions include, but
             are not limited to, inadequate medical history to assure study eligibility; and
             expectation of poor adherence to study requirements).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule, Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte gGmbH, Professor Hess Kinderklinik</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agenzia per L'emofilia e Centro Regionale Riferimento Coagulopatie Congenite</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cukurova Universitesi Tip Fakultesi</name>
      <address>
        <city>Balcali/Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi</name>
      <address>
        <city>Bornova/Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Cerrahpasa Tip Fakultesi</name>
      <address>
        <city>Fatih/Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derzhavna ustanova &quot;Instytut patolohii krovi ta transfuziinoi medytsyny Natsionalnoi akademii</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Georgia</country>
    <country>Greece</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Sweden</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3082B2-4434&amp;StudyName=Study%20of%20Safety%20And%20Efficacy%20Of%20ReFacto%20AF%20In%20Previously%20Untreated%20Hemophilia%20A%20Patients%20In%20The%20Usual%20Care%20Setting</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2009</study_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ReFacto AF</keyword>
  <keyword>factor VIII</keyword>
  <keyword>inhibitors</keyword>
  <keyword>antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 23, 2017</submitted>
    <returned>October 13, 2017</returned>
    <submitted>December 28, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

